Literature DB >> 627735

Experimental osteomyelitis. V. Therapeutic trials with oxacillin and sisomicin alone and in combination.

C W Norden.   

Abstract

Oxacillin was used alone and in combination with sisomicin in the treatment of experimental osteomyelitis due to Staphylococcus aureus in rabbits. Within diseased bone, levels of oxacillin and sisomicin remained higher than the minimal inhibitory concentration for 2 and 6 hr, respectively, after injection of 50 mg of oxacillin/kg and 10 mg of sisomicin/kg. Treatment with 50 mg of oxacillin/kg four times daily or 50 mg/kg every 4 hr around the clock for 28 days sterilized 30% of the rabbit bones. Sisomicin (10 mg/kg) injected twice daily for 28 days sterilized only 5% of the rabbit bones. In contrast, treatment with the combination of oxacillin and sisomicin for either 14 or 28 days was significantly more effective, sterilizing 78% and 85%, respectively, of the bones of treated animals. S. Aureus isolated from bones of animals treated with sisomicin alone contained aminoglycoside-resistant microcolonies. Resistant microcolonies were not recovered from animals treated with oxacillin or with the combination of oxacillin plus sisomicin. In vitro studies of bacterial killing by each antibiotic alone and in combination showed more bacterial killing with the combination than with either agent alone; in vitro the combination prevented emergence of resistant microcolonies. Combination antibiotic therapy appears to be more effective in treatment of experimental osteomyelitis due to S. aureus than therapy with a single agent.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 627735     DOI: 10.1093/infdis/137.2.155

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Use of synergistic antibiotics in the treatment of infections.

Authors:  J Righter; H Richardson
Journal:  Can Med Assoc J       Date:  1978-11-04       Impact factor: 8.262

Review 2.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

3.  Anaerobic resistance of clinical isolates of Staphylococcus aureus to aminoglycosides.

Authors:  L J Harrell; J B Evans
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

Review 4.  Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.

Authors:  P Noone
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 5.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

6.  In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.

Authors:  S H Zinner; J Klastersky; H Gaya; C Bernard; J C Ryff
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

7.  Experimental osteomyelitis due to Staphylococcus aureus or Pseudomonas aeruginosa: a radiographic-pathological correlative analysis.

Authors:  C W Norden; R L Myerowitz; E Keleti
Journal:  Br J Exp Pathol       Date:  1980-08

8.  Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics.

Authors:  T M Hooton; A D Blair; M Turck; G W Counts
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

9.  Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination.

Authors:  C W Norden; E Keleti
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.